ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

Inclusion Criteria: * Men and women, between 18 and 85 years, inclusive. * Subjects who are able and willing to give consent and able to attend all study visits. * A movement disorder symptom that has been deemed treatment-refractory by a movement disorder neurologist, including: o akathisia, akinesia, athetosis, bradykinesia, chorea, dystonia, tremor, myoclonus, dyskinesia, spasms, tics * Medication-refractoriness as determined by an adequate dose and duration of standard movement disorders treatment as determined by a specialist neurologist (e.g. a trial of primidone and propranolol for ET) * Able to communicate sensations during the ExAblate Neuro treatment * Stable doses of all medications for 30 days prior to study entry and for the duration of the study. Exclusion Criteria: * Patients with unstable cardiac status including: * Unstable angina pectoris on medication * Patients with documented myocardial infarction within six months of protocol entry * Congestive heart failure requiring medication (other than diuretic) * Patients on anti-arrhythmic drugs * Severe hypertension (diastolic BP \> 100 on medication) * Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc. * History of abnormal bleeding and/or coagulopathy (including deep venous thrombosis) * Cerebrovascular disease (multiple CVA or CVA within 6 months) * Symptoms and signs of increased intr…